In the evening of October 24, Beijing Hotgen Biotech Co., Ltd. (stock code: 688068) released its third quarter report for 2022. In the third quarter, Hotgen 's revenue and net profit continued to jump, achieving CNY 963 million revenue with a year-on-year increase of 391.95%

Hologic reported after the close of the market on Monday that a continued decline in sales of COVID-19 assays and ongoing difficulties securing semiconductor chips contributed to an overall 28 percent year-over-year decline in its fiscal fourth quarter revenues.

Myriad Genetics reported on Tuesday that its third quarter revenues fell 7 percent year over year primarily due to currency translations and change of estimates in diagnostic test cash collection, and non-recurring milestone payments.

BioMérieux announced on Wednesday that its third quarter revenues rose approximately 3 percent year over year due in part to unexpectedly strong sales in its BioFire product line.

On October 20, Sansure Biotech disclosed 2022 third quarter report, the company achieved revenue of CNY 4.068 billion in three quarters this year, an increase of 24.52% year-on-year; the net profit attributable to the mother achieved CNY 1.598 billion.

Oxford Nanopore Technologies reported on Tuesday morning that its revenues in the first half of 2022 more than doubled year over year, driven by COVID-19 testing.

Biocartis on Thursday reported a 21 percent year-over-year increase in revenues for the first half of 2022 as higher collaboration revenue offset a decline in SARS-CoV-2 product sales.

Burning Rock Biotech said Wednesday that its second quarter revenues were up about 3 percent year over year.

On August 26, Dian Diagnostics achieved operating income of CNY 10.753 billion, an increase of 85.68% over the same period last year; net profit attributable to the parent was CNY 1.880 billion, an increase of 158.54% over the same period last year.

In the first half of 2022, among the four major business lines of the company, the infectious disease business income reached 3.207 billion CNY, a significant increase of 240.32% over the same period of last year.